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Abstract
Background: Hepatic stellate cell (HSC) activation is activated mainly by endotoxin and transforming growth factor
(TGF-β1) in chronic liver injury, consequently, can be important therapeutic targets. Xia-yu-xue decoction (XYXD), a
classical recipe used in China to treat liver fibrosis, and has been revealed to inhibit hepatic fibrosis in animal models,
the mechanism of action of XYXD remains elusive. In the present study, we evaluated whether XYXD reduced
endotoxin and pro-fibrogenic pathways induced by lipopolysaccharide (LPS) and TGF-β1 in HSCs.
Methods: The in vivo effect of XYXD on fibrosis progression was assessed in mice model induced by carbon tetrachloride
(CCl4), The in vitro effect of XYXD on mice GFP-Col-HSC cells was evaluated using LPS and TGF-β1 stimulation.
Results: XYXD treatment reduced CCl4-induced liver fibrosis and decreased hepatic hydroxyproline (Hyp) content,
the mRNA levels of smooth muscle actin (α-SMA) and Col 1(α1) in fibrotic liver. XYXD suppressed nuclear factor-κB
(NF-κB) activation induced by LPS and TGF-β1 assessed by using NF-κB-luciferase reporter. The expression of NF-κB
target genes, chemokine (C-C motif) ligand 2 (CCL2) and chemokine (C-X-C motif) ligand 2 (CXCL2) induced by
LPS was suppressed after XYXD treatment. The expression of TGF-β1 targets genes, Col1(α1) and tissue inhibitor of
metalloproteinases (TIMP1) induced by TGF-β1 was inhibit after XYXD treatment.
Conclusion: XYXD treatment attenuates liver fibrosis by inhibiting HSC activation via inhibition of NF-κB and TGF-β1
signaling pathway, thereby blocking the synthesis of Col1 (α1) and TIMP-1. These findings from present study suggest
that XYXD may be a therapeutic decoction for liver fibrosis in which NF-κB and TGF-β1 are thought to take part.
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Background
Liver fibrosis, defined by redundant deposition of extra-
cellular matrix (ECM) and resultant loss of soft and liver
function, is the result of wound-healing responses stimu-
lated by various liver injury [1, 2]. In response to liver
injury, quiescent hepatic stellate cells (HSCs) are activated
and develop a myofibroblast-like phenotype that expresses
smooth muscle actin (α-SMA) and profibrogenic genes [3].
HSC activation, the most important event in liver fibrosis,
is mediated by many inflammatory and fibrogenic cytokines
released from the damaged hepatocytes, circulatory system
or from Kupffer cells (KCs). The events subsequent to HSC
activation, including the augmented production of collagen,
are crucial for the hepatic fibrogenesis cascade. Thus, the
HSC activation is an appealing target for the develop-
ment of new antifibrotic drugs [4, 5].
Xia-yu-xue decoction (XYXD) is a classical recipe
from Jin Kui Yao Lue (Synopsis of the Golden Chamber)
in 200 AD that has a long history in traditional Chinese
medicine. XYXD consists of three medicinal herbs,
Radix et Rhizoma Rhei (10 g), Semen Persicae (10 g),
and Eupolyphaga Seu Steleophaga (6 g). XYXD was used
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widely in clinical for treatment liver fibrosis patients
without side effects [6]. It was reported that XYXD
could regulate the balance of MMP2,9/TIMP1,2 in re-
sponse to LPS stimulation in RAW264.7 cells [7] and in-
hibit KC activation in pig serum induced liver fibrosis in
rats [8]. There was reported that XYXD exerts thera-
peutic effects by inhibiting HSC activation in carbon
tetrachloride (CCl4)-induced liver fibrosis in mice [9].
However, scant information is available regarding the
antifibrotic mechanism of XYXD action in HSC activa-
tion in vitro and in vivo.
Lipopolysaccharide (LPS) level increased in liver fibro-
sis from portal and systemic circulation owing to
changes in the intestinal mucosal permeability [10].
Toll-like receptor 4 (TLR4) signaling pathway is acti-
vated upon LPS stimulation, and induces nuclear factor-
κB (NF-κB) activation, which leads to the transcription
of inflammatory genes, such as chemokine (C-C motif )
ligand 2 (CCL2) and chemokine (C-X-C motif ) ligand 2
(CXCL2) in HSCs. We previously showed that LPS
stimulation enhanced the response of HSCs to trans-
forming growth factor (TGF-β1) [11]. One the other
hand, TGF-β1 derived from injured hepatocytes, acti-
vated KCs, increased and bound to TGF receptor in
HSCs in chronic liver injury. Thereafter, the downstream
signaling such as Smad2/3 phosphorylate, which induce
the transcription of pro-fibrogenic genes, such as Col1
(α1) and TIMP1. We hypothesize that XYXD suppresses
the LPS-mediated inflammatory signaling through the
suppression of NF-κB and TGF-β1-mediated fibrogeinc
signaling, thereby attenuating inflammation and profi-
brogenic response in HSCs.
Consequently, in the present study we applied the
CCl4 model to examine the anti-fibrotic effects of XYXD
in the mice liver. The anti-fibrotic activities were evalu-
ated by histopathology, hepatic hydroxyproline content,
and mRNA expression of α-SMA and collagen 1(α1)
in vivo. Because the importance of LPS and TGF-β1 in
hepatic fibrosis, in vitro we detected the possibility that
the anti-fibrotic activities of XYXD might act through




XYXD consists of crude slices were purchased from
Shanghai Huayu Chinese Herbs Co Ltd (China) [12] and
from the following ratios of three medicinal herbs: Radix
et Rhizoma Rhei 10 g (2 kg, Cat No:140501), Semen
Persicae 10 g (2 kg, Cat No:140619), and Eupolyphaga
Seu Steleophaga 6 g (1.2 kg, Cat No: 141110), total
weight 5.2 kg. The medicines were accredited by a
pharmacologist. The medicinal mixture was extracted by
extracted with 75 % ethanol twice, then infiltration and
the resulting ethanol extracts were evaporated and dehy-
drated under vacuum. The extract powder was weighed
(0.585 kg) and used for the experiments by dissolving in
pure water or DMEM at the desired concentrations for
in vivo and in vitro studies.
Ethics statement
All of the study protocols complied with the current eth-
ical considerations of Shanghai University of Traditional
Chinese Medicine’s Animal Ethic Committee and the
procedural and ethical guidelines of the Chinese Animal
Protection Act, which is in accordance with the National
Research Council criteria. All animal experiments and
procedures were reviewed and approved by the Institu-
tional Animal Care and Use Committee (IACUC) of
Shanghai University of Traditional Chinese Medicine
and were performed in accordance with the relevant
guidelines and regulations.
In vivo CCl4-induced liver fibrosis
Male C57BL/6 mice at 6–8 week (18–20 g) were housed
in an air-conditioned room at 25 °C with a 12 h dark/
light cycle. The mice received humane care during the
study with unlimited access to chow and water. The
mice were randomized into two groups: the normal (n =
10) and CCl4-treated group (n = 30). The CCl4-treated
mice were treated with 10 % CCl4 (2 mg/kg of body
weight i.p.) diluted in corn oil or with corn oil only (nor-
mal) for triweekly and distilled water (by gavage) daily,
The CCl4-treated mice then divided into CCl4-water
(CCl4, n = 20) and CCl4-XYXD (XYXD, n = 10) from the
beginning of first CCl4-treatment. At the end of the
third week, 10 mice from the CCl4-treated group were
sacrificed for the fibrosis development assessment. The
XYXD treatment group was exposed to the same level of
CCl4 and administered XYXD at a dose of 0.467 g/100 g
body weight, which is equivalent to human doses in clin-
ical therapeutics daily for 6 weeks until sacrifice.
Hydroxyproline (Hyp) determination
Hepatic hyp content was used as an indirect measure of
tissue collagen content. Hyp from liver tissues (50–
100 mg) was determined according to the paper we pub-
lished previously [13].
In vitro cell culture and treatment
The mouse HSC cell line GFP-Col-HSC was provided by
Dr. Ekihiro Seki (School of Medicine, University of
California San Diego, CA) and cultured in DMEM with
10 % FBS and 1 % penicillin-streptomycin antibiotics.
XYXD was dissolved with vehicle (DMEM). HSCs were
serum starved for 12 h, the GFP-Col-HSCs first treated
with XYXD (5, 25 μg/ml) for 1 h, the cells then treated
with or without LPS (100 ng/ml) or TGF-β1 (10 ng/ml).
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Reagents
LPS (Sigma; Escherichia coli serotype 055:B5), recombin-
ant human TGF-β1 (R&D Systems) were used in this
study. The antibodies used for the western blot analysis,
and are p-JNK (catalog no. sc-81502), JNK (catalog no.
sc-7345), p38 (catalog no. sc-398305), p-p38 (catalog no.
sc-17852-r), p-Smad2 (catalog no. sc-101801), Smad2
(catalog no. sc-39312), p-Smad3 (catalog no. sc-101154),
and Smad3 (catalog no. sc-130218), all purchased from
Santa Cruz Biotechnology, Inc. NF-κB inducible reporter
plasmid were purchased from InvivoGen (cat no:
pnifty2-luc, San Diogo, CA). Lipofectamine 2000 trans-
fection regent was purchased from Invitrogen.
NF-κB luciferase analysis
The GFP-Col-HSC was transfected with the NF-κB in-
ducible reporter plasmid by Lipofectamine 2000 for 12–
18 h. The cells were first treated with XYXD (5, 25 μg/
ml) for 1 h before treatment with 100 ng/mL LPS or
10 ng/mL TGF-β1. Luciferase activity was measured
after 16 h of the treatment with LPS or TGF-β1. Lucifer-
ase activity was normalized to the protein concentration
of GFP-Col-HSC in each well.
Measurement GFP-Col-HSC activation
The GFP-Col-HSC normal culture and supplement with
XYXD (5, 25 μg/ml) for 36 h. The fluorescent signal
HSC was then measured by fluorescent microscopy.
Quantitative real-time PCR
Total RNA was extracted using TRIzol (Life Technologies,
Grand Island, NY), followed by reverse transcription of
total RNA to cDNA. cDNA was synthesized using a high-
capacity cDNA reverse transcription kit (Applied Biosys-
tems, Foster city, CA). cDNA subsequently underwent
quantitative real-time polymerase chain reaction (PCR)
using the ABI ViiA™ 7 Dx real-time PCR system (Life
Technologies, Grand Island, NY). PCR primer sequences
used were used: 18 s rRNA forward 5’-AGTCCC
TGCCCTTTGTACACA-3’. 18 s rRNA reverse 5’-CGA
TCCGAGGGCCTCACTA-3’. Bambi forward 5’- TGAGC
AGCATCACAGTAGCA-3’. Bambi reverse 5’- CGCC
ACTCCAGCTACTTCTT-3’. TIMP1 forward 5’- AGGTG
GTCTCGTTGATTCGT-3’. TIMP1 reverse 5’- GTAAGG
CCTGTAGCTGTGCC-3’. CCL2 forward 5’- ATTGGG
ATCATCTTGCTGGT-3’. CCL2 reverse 5’- CCTGCTGT
TCACAGTTGCC-3’. CXCL2 forward 5’- TCCAGGTC
AGTTAGCCTTGC-3’. CXCL2 reverse 5’- CGGTCAA
AAAGTTTGCCTTG-3’. PPAR-γ forward 5’- AACTCCC
TCATGGCCATTGA-3’. PPAR-γ reverse 5’- GCATTG
TGAGACATCCCCAC-3’. Col 1(α1) forward 5’-TAGGC
CATTGTGTATGCAGC-3’. Col 1(α1) reverse 5’-ACAT
GTTCAGCTTTGTGGACC-3’. α-SMA forward 5’-GTTC
AGTGGTGCCTCTGTCA-3’. α-SMA reverse 5’- ACTG
GGACGACATGGAAAAG-3’. Gene expression was nor-
malized to 18 s RNA as an internal normal.
Western blot
Cell samples were prepared in radio immunoprecipitation
lysis buffer containing protease inhibitors. After protein
quantification, protein samples at 20 μg/lane were sub-
jected to polyacrylamide gel electrophoresis, and then in-
cubated with antibodies for phospho-JNK, JNK, p-p38,
p38, p-Smad 2, Smad2, p-Smad 3, Smad 3 with appro-
priate secondary horseradish peroxidase (HRP)-conju-
gated antibodies, and developed. Anti-glyceraldehyde
3-phosphate dehydrogenase mouse antibody was pur-
chased from Kangchen and diluted in 1:5000 ratio.
Immunohistochemistry
The sections were dewaxed in xylene and dehydrated in
alcohol. Antigen retrieval was achieved by microwaving
in citric saline at 95 °C for 3 min. Thin sections were
treated with 3 % hydrogen peroxide for 10 min. The sec-
tions were further blocked by 5 % BSA and were then
incubated 37 °C with primary antibody against α-SMA
(Abcam, UK). The sections were incubated with bio-
tinylated secondary antibody (Boster, Wuhan, China) for
30 min at room temperature. α-SMA expressions were
visualized by DAB (Boster, Wuhan, China) staining.
Statistics
Differences between two groups were compared using
the two-tailed unpaired student t-test. Differences be-
tween multiple groups were compared using one-way
ANOVA with a post hoc Dunnett’s test using SPSS 18.0.
P values, 0.05 were considered significant. All experi-
ments were performed at least three times and the rep-
resentative data were presented.
Results
Inhibition of CCl4-induced liver fibrosis by XYXD
CCl4 is known to induce toxicity in the liver by produ-
cing highly reactive metabolites, which severely damage
hepatocytes and subsequent fibrosis [14]. As shown in
Fig 1a, livers of normal mice showed normal lobular
architecture with central vein and radiating hepatic
cords. After 3 weeks of CCl4 treatment, liver centrilobu-
lar necrosis, deposition of lipid droplets in hepatocytes,
and inflammatory cells infiltration were observed. After
6 weeks CCl4 treatment, liver sections revealed collagen
deposition, severe fatty changes, whereas, concomitant
treatments of XYXD significantly inhibited CCl4-in-
duced hepatic damage, as indicated by decreases in he-
patocytes degeneration, inflammation, and collagen
deposition (Fig 1a).
Sirius red staining revealed that mice treated with CCl4
for 3 weeks showed prominent red staining in collagen
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was seen to stretch from portal area to lobular (Fig. 1b).
Livers showed marked distortion in architecture, includ-
ing portal and lobular bridging fibrosis, cirrhotic nodule
formation. Collagen fiber percentages in the CCl4
groups were significantly decreased in XYXD treated
mouse livers.
HSC activation was inhibited by XYXD in vivo
As sustained deposition of ECM results mainly from
HSC activation, α-SMA is a marker of HSCs in hepatic
fibrosis [15], and the α-SMA-positive cells are increased
gradually in number, mainly located in fibrotic septa fol-
lowing 6 week CCl4-treatment. In contrast, a marked re-
duction of α-SMA-positive HSCs was observed in
XYXD liver compared with 6 weeks CCl4 liver (6 wk)
(Fig 2a).
The expression of α-SMA in CCl4-treated liver sam-
ples was also detected by real-time PCR analyses (Fig 2b).
The expression of α-SMA and Col 1(α1) increased grad-
ually following CCl4 treatment (Fig 2b and c). Compared
to 6 weeks CCl4 treatment liver (6 wk), XYXD adminis-
tration resulted in marked reductions in α-SMA and Col
1(α1) (P < 0.05). Hepatic hyp content increased in CCl4-
treated mice gradually, after 3-week CCl4 administration,
the Hyp content was 206 % of that in the normal group
(P < 0.05) (Fig 2d). XYXD was found to decrease liver
Hyp content significantly (P < 0.01).
The effect of XYXD on HSCs activation in vitro
To reveal the mechanisms responsible for these in vivo
observations, we performed in vitro studies using GFP-
Col-HSC cells, a well-characterized mouse HSC cell line.
First, we tested the cytotoxicity of XYXD, as assessed by
cell viability. MTT assay showed no significant difference
between normal and XYXD treated cells at concentra-
tions 25 μg/ml (data not shown here). Therefore, we
used 25 μg/ml of XYXD in subsequent experiments.
Effects of XYXD on LPS signaling in HSC
We examine whether XYXD inhibits the LPS signaling
in HSC. It has been reported that NF-κB activation in
HSC is associated with sustained liver inflammation
[16]. We investigated the effect of XYXD on NF-κB ac-
tivity in HSCs. The luciferase array analysis showed that
the relative luciferase activity increase significantly 4-
fold (P < 0.01) with LPS treatment (Fig. 3a) in HSCs. In
contrast, treatments at 5 and 25 μg/ml one hour prior to
LPS treatment significantly suppressed the LPS-induced
NF-κB activation (P < 0.05 or 0.01) (Fig 3a). In addition
to NF-κB, JNK and MAPK are also activated by LPS in
HSC. We therefore examined the effect of XYXD on
JNK and MAPK activation. JNK and p38 were quickly
phosphorylated in HSC in response to LPS stimulation
(Fig 3b). The LPS-mediated JNK and MAPK activation
was reduced by XYXD treatment (Fig 3b). We previously
reported that Bambi decreased in response to LPS
stimulation [11], as expected, LPS treatment increased
TIMP1 and decreased Bambi in GFP-Col-HSC cells
(Fig 3c) (P < 0.05 or 0.01). The XYXD significantly re-
duced the expression of LPS-induced TIMP1 in HSC
(P < 0.05 or 0.01). XYXD could inhibit Bambi decrease
induced by LPS stimulation (Fig 3c) (P < 0.05 or 0.01).
Fig. 1 Effects of Xia-yu-xue decoction (XYXD) on histological changes in CCl4-induced liver fibrosis in mice. a HE staining (×100), (b) Sirius red
staining (×100). CCl4 (10 %, 2 mg/kg of body weight) was administered intraperitoneally to CCl4-treatment mice for tri-weekly and distilled water
(by gavage) daily for 6 weeks. The normal mice received an equal amount of corn oil and distilled water (by gavage) daily for 6 weeks. At the
end of the third week, 10 CCl4-treated mice were for the fibrosis development assessment. The XYXD treatment group was exposed to the same
level of CCl4 and administered XYXD at a dose of 0.467 g/100 g body weight, which is equivalent to human dose in clinical therapeutics daily for
6 weeks until sacrifice. The number in HE and Sirius red staining was as the same as the animal number in each group
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Because NF-κB induces an inflammatory response in
the liver, we investigated whether XYXD can suppress
the induction of inflammatory cytokines in HSC. The
pro-inflammatory cytokines of CCL2 and CXCL2 were
up-regulated after LPS stimulation (Fig 3d) (P < 0.01).
The mRNA expression CCL2 and CXCL2 was signifi-
cantly inhibited by XYXD treatment (Fig 3d) (P < 0.05 or
0.01). These results demonstrated that LPS-induced sig-
naling was inhibited by XYXD in HSC.
Effect of XYXD on TGF-β1 signaling in HSC
TGF-β1 is a classic activator of HSCs and a key medi-
ator in the pathogenesis of liver fibrosis [17]. However, it
was rarely reported NF-κB activated in response to
TGF-β1 stimulation in HSCs. We assessed NF-κB activ-
ity by using the NF-κB luciferase reporter system. TGF-
β1 treatment significantly increased NF-κB activity (P <
0.01) in HSCs (Fig 4a) (P < 0.05 or 0.01). XYXD treat-
ments 1 h prior to TGF-β1 treatment significantly sup-
pressed the TGF-β1-induced NF-κB activation (P < 0.05).
The TGF-β1-mediated signaling pathway depends on
the phosphorylation of Smad 2/3. As shown in Fig 4b,
the protein levels of Smad 2/3 were analyzed. Western
blot analysis detected increases in the phosphorylation
of Smad 2/3 by TGF-β1, and the inhibition of these in-
creases by XYXD (Fig. 4b). Also, the mRNA expression
of Col1 (α1) and TIMP1 significantly increased in re-
sponse to TGF-β1 stimulation (P < 0.01). XYXD treat-
ment suppress Col1 (α1) and TIMP1 mRNA expression
(Fig 4c) (P < 0.05 or 0.01). These results indicated that
XYXD inhibited TGF-β1-induced HSC activation.
Effect of XYXD on fibrogenic response induced by LPS
plus TGF-β1 in HSC
TGF-β1 treatment increased Col 1(α1) mRNA expres-
sion in GFP-Col-HSC cells (Fig. 5), LPS treatment
further increased Col 1(α1) mRNA expression in GFP-
Col-HSC cells (Fig. 5a) (P < 0.05 or 0.01). While, XYXD
treatment resulted in dose-dependent decrease in colla-
gen synthesis in GFP-Col-HSC cells (P < 0.05 or 0.01).
Increased TIMP-1 expression was inhibited by XYXD,
with a significantly reduction at the 5 and 25 μg/ml dose
level in GFP-Col-HSC cells (Fig 5b) (P < 0.05 or 0.01).
Effect of XYXD on full activated HSC
As shown in Fig 6a, GFP-Col-HSC cell full activated
after 36 h culture by measuring GFP fluorescent signal.
XYXD treatments at 5 μg/ml and 25 μg/ml suppressed
GFP-Col-HSC activation (Fig 6a). The mRNA expression
of α-SMA and TIMP1 was decreased significantly by
XYXD treatment (Fig 6b and c) (P < 0.05 or 0.01). Mean-
while, XYXD increased PPARγ mRNA level compared
with vehicle group (Fig 6d) (P < 0.01). These results
showed that GFP-Col-HSC auto-activated after 36 h cul-
ture, and XYXD could inhibit GFP-Col-HSC activation.
Discussion
Xia-yu-xue decoction (XYXD) has used in China for
more than 2 thousand years without side effects.
Fig. 2 Effects of XYXD on HSC activation and Col production in CCl4-induced liver fibrosis in mice. a, liver sections were stained with α-SMA (×200,
n = 3), Brown staining indicates immunopositivity. b, Expression of α-SMA was analyzed using real-time PCR analysis (n = 6). c, Expression of Col 1(α1)
was analyzed using real-time PCR analysis (n = 6). d, Hyp content of liver tissue was measured. The number in Hyp and Sirius red detection was as the
same as the animal number in each group. The data represented the mean ± SD *P < 0.05, * *P < 0.01, vs normal mice, #P < 0.05, ##P < 0.01, vs 6 wk
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However, the anti-fibrotic mechanism of action of XYXD
was very limited. In an effect to investigate the inhibitory
effect of XYXD on HSC activation, we used (1) CCl4-in-
duced liver fibrosis in mice in vivo, and (2) an in vitro
model based on GFP-Col-HSC cells treated with or with-
out LPS, TGF-β1 or both. The data demonstrated that
XYXD treatment inhibited the accumulation of ECM
components in CCl4-induced liver fibrosis in vivo. XYXD
is capable of inhibiting HSC cellular activated by LPS and
TGF-β1 in GFP-Col-HSC lines.
Chronic liver disease commonly leads to liver fibrosis,
resulting in development of liver cirrhosis, organ failure,
and eventually liver related mortality. Therefore, preven-
tion or treatment of liver fibrosis is the main target in
patients with chronic hepatic disorders [18]. Recently,
much interest in herbal medicine has been focused on
hepato-protective or anti-fibrotic effects. Although lack
of strong clinical evidence, many traditional Chinese
medicine/recipes/decoctions and drugs such as Yin-
chen-hao decoction [13], Xiao-chai-hu decoction (sho-
saiko-to in Japan) [19, 20] are used widely in China,
Korea, and Japan for thousands of years and reported to
have antifibrotic properties. Just like Yin-chen-hao de-
coction (Inchinko-to in Japan) and Xiao-chai-hu decoc-
tion (sho-saiko-to, in Japan), Xia-yu-xue decoction first
described in Shanghan Lun, while, there were rare lim-
ited information about the anti-fibrotic effects of XYXD.
So it is very urgent to investigate the mechanism of ac-
tion of XYXD. In this study, we found XYXD inhibit α-
SMA and Col 1(α1) expression, which indicating HSC
Fig. 3 The suppression of LPS-induced signaling by pretreatment of XYXD in HSC. a, NF-κB luciferase was measured. One hour after pretreatment with
XYXD (5ug/ml and 25 ug/ml), GFP-Col-HSC cells were treated with LPS (100 ng) for 4 h and then transfected NF-κB-luciferase reporter plasmid for
16 h. *P < 0.05, * *P < 0.01, vs Un-LPS and No XYXD, #P < 0.05, ##P < 0.01, vs LPS and No XYXD. b, Western blot analysis for p-JNK, total JNK, p-p38 and
total p38. One hour after pretreatment with XYXD (5 μg/ml and 25 μg/ml), GFP-Col-HSC cells were treated with LPS (100 ng) for 30 min. c, the mRNA
expression of TIMP1 and Bambi was detected by real-time PCR. *P < 0.05, * *P < 0.01, vs vehicle, #P < 0.05, ##P < 0.01, vs LPS. d, the mRNA expression of
CCL2 and CXCL2 was detected by real-time PCR. One hour after pretreatment with XYXD (5 μg/ml and 25 μg/ml), GFP-Col-HSC cells were treated with
LPS (100 ng) for 4 h. *P < 0.05, * *P < 0.01, vs vehicle, #P < 0.05, ##P < 0.01, vs LPS. Data represent the mean ± SD of triplicate cultures. A representative
result is shown. Similar results were obtained in three independent experiments
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activation were suppressed in CCl4-induced liver fibrosis
in vivo.
LPS levels increase in the systemic circulation owing
to changes in the intestinal mucosal permeability after
liver injury [21, 22]. LPS plays a key role in hepatic fibro-
genesis by enhancing HSC activation [23]. NF-κB acti-
vated in response to LPS-mediated TLR4 activation [24].
So we want to know whether XYXD inhibit LPS signal-
ing through NF-κB. In the present study, NF-κB lucifer-
ase increased in response to LPS stimulation and was
inhibited significantly by XYXD treatment. Our study
also demonstrated that XYXD suppressed both JNK and
p38 signaling pathways induced by LPS. Furthermore,
we approved that the mRNA expression of CCL2 and
CXCL2 was also suppressed by pretreatment with
XYXD.
In response to liver injury, HSCs undergo activation
process and produce ECM [25]. The process is primed by
various growth factors, where TGF-β1 is the most
Fig 5 Effect of XYXD on fibrogenic response induced by LPS plus
TGF-β1 in HSC. Col 1(α1) (a), TIMP1 (b) was measure by real-time
PCR analysis. GFP-Col-HSC cells were pretreated with XYXD (5 μg/ml
and 25 μg/ml) for 1 h and subsequently treated with LPS for 12 h,
then treated with TGF-β1 (10 ng/ml) for 24 h . Data represent the
mean ± SD of triplicate cultures. *P < 0.05, * *P < 0.01, vs no LPS/TGF-
β1, #P < 0.05, ##P < 0.01, vs vehicle. A representative result is shown.
Similar results were obtained in three independent experiments
Fig. 4 Effect of XYXD on TGF-β1-induced signaling in HSC. a, NF-κB
luciferase was measured. GFP-Col-HSC cells were pretreated with
XYXD (5 μg/ml and 25 μg/ml) for 1 h and subsequently treated with
TGF-β1 (10 ng/ml) over night, followed by transfect NF-κB-luciferase
reporter plasmid for 16 h. *P < 0.05, * *P < 0.01, vs Un-TGF-β1 and No
XYXD, #P < 0.05, ##P < 0.01, vs TGF-β1 and No XYXD. b, western blots
analysis were analysis for p-Smad2, total smad2, p-smad3, and total
Smad3. GFP-Col-HSC cells were pretreated with XYXD (5 μg/ml and
25 μg/ml) for 1 h and subsequently treated with TGF-β1 (10 ng/ml)
for 30 min. c, the Col1(α1) and TIMP1was measure by real-time PCR.
GFP-Col-HSC cells were pretreated with XYXD (5 μg/ml and 25 μg/
ml) for 1 h and subsequently treated with TGF-β1 (10 ng/ml) for
24 h. Data represent the mean ± SD of triplicate cultures. *P < 0.05, *
*P < 0.01, vs vehicle, #P < 0.05, ##P < 0.01, vs TGF-β1. A representative
result is shown. Similar results were obtained in three
independent experiments
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important profibrogenic mediator. It was well reported
the pro-inflammatory cytokine through NF-κB enhance
TGF-β1 signaling [1, 23]. However, whether TGF-β1 could
induce NF-κB activation was largely unknown. Our results
showed that NF-κB activity increased almost 2-fold in re-
sponse to TGF-β1 stimulation, and XYXD could inhibit
NF-κB activity induced by TGF-β1. Moreover, the signal-
ing pathway activated by TGF-β1 involves phosphoryla-
tions of Smad 2 and Smad 3 [26, 27], which were also
inhibited by XYXD. These data suggest that XYXD blocks
fibrogenesis as mediated by TGF-β1 signaling pathways.
We used LPS plus TGF-β1 to mimics the complex en-
vironment in vivo. The mRNA expression of Col 1(α1) and
TIMP1 increased significantly using LPS plus TGF-β1
stimulation compared with TGF-β1 alone in GFP-Col-HSC
cell line. However, XYXD treatment decreased the en-
hancement of TGF-β1 plus LPS-induced Col 1(α1) and
TIMP1 mRNA expression. This may be due to the inhibi-
tory effect of XYXD on NF-κB and TGF-β1 signaling, and
the further mechanism should be studies in future research.
Conclusions
This study demonstrated that XYXD reduce HSC activa-
tion in CCl4-induced liver fibrosis in mice. The inhibitory
effects of XYXD on HSC activation may be caused, at least
in part, by suppressing on NF-κB and TGF-β1 signaling
pathway.
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Fig. 6 The effect of XYXD on full activated HSC. GFP-Col-HSC cells were plated and cultured in 6-well plates for 2 h, then treated with XYXD
(5 μg/ml and 25 μg/ml) for 36 h followed by fluorescent microscopy(×100, n = 3). Representative pictures are shown (a). α-SMA (b), TIMP1 (c),
and PPARγ (d) were measure by real-time PCR analysis. The data represented the mean ± SD, #P < 0.05, ##P < 0.01, vs vehicle. A representative
result is shown. Similar results were obtained in three independent experiments
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